Skip to main content

Harrow, Inc.

corporate_fare Company Profile

Harrow, Inc.

HROW·NASDAQ·Life Sciences·CIK 0001360214

Harrow is a leading provider of ophthalmic disease management solutions in North America. The company was founded to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For over a decade, Harrow has partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye. These conditions include dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow has expanded its portfolio of U.S. Food and Drug Administration (FDA)-approved ophthalmic products through acquisitions, licensing transactions, and internal investment, primarily focusing on the U.S. and Canadian markets. The company owns U.S. commercial rights to and markets the following products: IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, a low-viscosity gel for ocular surface anesthesia; VEVYE® (cyclosporine ophthalmic solution) 0.1%, a water-free solution for the signs and symptoms of dry eye disease; TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/ml, a steroid injection for certain ophthalmic diseases and vitrectomy visualization; and BYOOVIZ® (ranibizumab-nuna) 0.05mL injection, the first FDA-approved LUCENTIS biosimilar for Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV).

Harrow, Inc. (NASDAQ:HROW) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for HROW at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for HROW spans 10-Q, 8-K, 4, 10-K.

Recent high-impact activity:

  • Harrow 10-Q: Record Q3 Revenue $99.3M, $9.8M Net Income; VEVYE Licensor Consent Risk on TYRVAYA
  • Harrow Q3 Revenue $99.3M but Adjusted EBITDA Guidance Cut to $40M+ from $80-100M
  • Harrow Posts 25c Q3 EPS, Swinging to Profit From Prior Loss
  • Harrow Closes TYRVAYA Acquisition with Revised Terms: Japan Rights Retained by Viatris, $30M Fixed Cash Consideration
  • Iheezo Cuts Eye-Injection Discomfort 58% in Head-to-Head Study

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$272.3M
Net Income
-$5.14M
Diluted EPS
-$0.14
Op. Cash Flow
$43.86M
Free Cash Flow
$42.98M
Gross Profit
$204.37M
Operating Income
$30.52M
Cash & Equivalents
$72.93M
Debt / Equity
0.00×
Net Margin
-1.9%
Shares Outstanding
37.23M sh
Source: 10-K · filed 2026-03-02 · accession 0001493152-26-008562

Short Interest & Short Volume

14.13 days to cover

FINRA reported short interest of 7,092,437 shares in HROW as of the October 30, 2026 settlement, a 5.1% decrease from the prior period — about 14.1 days to cover at its recent average daily volume. On November 20, 2026, 60.2% of HROW volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,092,437 shares as of October 30, 2026
Change vs prior period▼ 5.1%
Days to cover14.13 at avg daily volume of 502,072
Daily short volume (FINRA facilities)60.2% of 348,433 shares on November 20, 2026
5-day average short volume62.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with H →
$30.3 -0.36% today
52-week range · as of 2026-11-09 $25.76 – $54.85
Market cap
$1.14B
Volume
911.8K (1.3× avg)
3-mo avg 692.7K
Live data · 2026-11-21 12:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HROW - Latest Insights

HROW
Nov 09, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.90
Real-time Price: $30.30 info
Change: -$1.60 (-5%) info
Market Cap: $1.141B info
HROW
Nov 09, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.14
Real-time Price: $30.30 info
Change: -$0.843 (-3%) info
Market Cap: $1.141B info
HROW
Nov 09, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $27.44
Real-time Price: $30.30 info
Change: +$2.86 (+10%) info
Market Cap: $1.141B info
HROW
Oct 05, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.90
Real-time Price: $30.30 info
Change: -$0.600 (-2%) info
Market Cap: $1.141B info
HROW
Aug 21, 2026, 12:09 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $41.61
Real-time Price: $30.30 info
Change: -$11.31 (-27%) info
Market Cap: $1.141B info
HROW
Aug 10, 2026, 4:28 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $40.05
Real-time Price: $30.30 info
Change: -$9.75 (-24%) info
Market Cap: $1.141B info
HROW
Aug 10, 2026, 4:19 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $40.11
Real-time Price: $30.30 info
Change: -$9.81 (-24%) info
Market Cap: $1.141B info
HROW
Aug 10, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.50
Real-time Price: $30.30 info
Change: -$10.20 (-25%) info
Market Cap: $1.141B info
HROW
Aug 06, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $40.00
Real-time Price: $30.30 info
Change: -$9.70 (-24%) info
Market Cap: $1.141B info
HROW
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $40.00
Real-time Price: $30.30 info
Change: -$9.70 (-24%) info
Market Cap: $1.141B info
HROW
Jun 10, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.59
Real-time Price: $30.30 info
Change: -$3.29 (-10%) info
Market Cap: $1.141B info
HROW
May 11, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $34.14
Real-time Price: $30.30 info
Change: -$3.84 (-11%) info
Market Cap: $1.141B info
HROW
May 11, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.03
Real-time Price: $30.30 info
Change: -$5.73 (-16%) info
Market Cap: $1.141B info
HROW
Mar 27, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $33.83
Real-time Price: $30.30 info
Change: -$3.53 (-10%) info
Market Cap: $1.141B info
HROW
Mar 24, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $33.60
Real-time Price: $30.30 info
Change: -$3.30 (-10%) info
Market Cap: $1.141B info
HROW
Mar 24, 2026, 8:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $33.60
Real-time Price: $30.30 info
Change: -$3.30 (-10%) info
Market Cap: $1.141B info
HROW
Mar 10, 2026, 8:26 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.29
Real-time Price: $30.30 info
Change: -$4.99 (-14%) info
Market Cap: $1.141B info
HROW
Mar 05, 2026, 4:05 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $36.50
Real-time Price: $30.30 info
Change: -$6.20 (-17%) info
Market Cap: $1.141B info
HROW
Mar 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $45.90
Real-time Price: $30.30 info
Change: -$15.60 (-34%) info
Market Cap: $1.141B info
HROW
Mar 02, 2026, 4:31 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $46.55
Real-time Price: $30.30 info
Change: -$16.25 (-35%) info
Market Cap: $1.141B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets